Page last updated: 2024-09-05

ibogaine and Depression

ibogaine has been researched along with Depression in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (33.33)	29.6817
2010's	1 (33.33)	24.3611
2020's	1 (33.33)	2.80

Authors

Authors	Studies
Anderson, EI; Brown, BM; Cameron, LP; Dunlap, LE; Ehinger, Y; Fiehn, O; Hurley, ZQ; Kokel, D; Laskowski, LJ; Lein, PJ; Liu, T; Lu, J; McCarroll, MN; McCorvy, JD; Myers-Turnbull, D; Olson, DE; Pell, AJ; Peters, J; Rabow, ZT; Ron, D; Taylor, JC; Tjia, M; Tombari, RJ; Vargas, MV; Viswanathan, J; Wulff, H; Yaghoobi, B; Zhang, G; Zuo, Y	1
Frampton, CM; Noller, GE; Yazar-Klosinski, B	1
Ervin, FD; Kovera, CA; Mash, DC; Mayor, M; Pablo, J; Singleton, EG; Tyndale, RF; Williams, IC	1

Trials

1 trial(s) available for ibogaine and Depression

Article	Year
Ibogaine: complex pharmacokinetics, concerns for safety, and preliminary efficacy measures. Annals of the New York Academy of Sciences, 2000, Volume: 914 Topics: Adult; Cocaine; Depression; Dose-Response Relationship, Drug; Excitatory Amino Acid Antagonists; Female; Humans; Ibogaine; Male; Narcotics; Substance-Related Disorders; Surveys and Questionnaires; Time Factors	2000

Other Studies

2 other study(ies) available for ibogaine and Depression

Article	Year
A non-hallucinogenic psychedelic analogue with therapeutic potential. Nature, 2021, Volume: 589, Issue:7842 Topics: Alcoholism; Animals; Antidepressive Agents; Arrhythmias, Cardiac; Behavior, Addictive; Chemistry Techniques, Synthetic; Depression; Disease Models, Animal; Drug Design; Female; Hallucinogens; Heroin Dependence; Ibogaine; Male; Mice; Mice, Inbred C57BL; Neuronal Plasticity; Patient Safety; Receptor, Serotonin, 5-HT2A; Serotonin 5-HT2 Receptor Agonists; Substance-Related Disorders; Swimming; Tabernaemontana	2021
Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study. The American journal of drug and alcohol abuse, 2018, Volume: 44, Issue:1 Topics: Adult; Depression; Female; Follow-Up Studies; Hallucinogens; Humans; Ibogaine; Male; Middle Aged; Opioid-Related Disorders; Substance Withdrawal Syndrome; Treatment Outcome	2018

Article

Year

A non-hallucinogenic psychedelic analogue with therapeutic potential.

Nature, 2021, Volume: 589, Issue:7842

Topics: Alcoholism; Animals; Antidepressive Agents; Arrhythmias, Cardiac; Behavior, Addictive; Chemistry Techniques, Synthetic; Depression; Disease Models, Animal; Drug Design; Female; Hallucinogens; Heroin Dependence; Ibogaine; Male; Mice; Mice, Inbred C57BL; Neuronal Plasticity; Patient Safety; Receptor, Serotonin, 5-HT2A; Serotonin 5-HT2 Receptor Agonists; Substance-Related Disorders; Swimming; Tabernaemontana

2021

Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study.

The American journal of drug and alcohol abuse, 2018, Volume: 44, Issue:1

Topics: Adult; Depression; Female; Follow-Up Studies; Hallucinogens; Humans; Ibogaine; Male; Middle Aged; Opioid-Related Disorders; Substance Withdrawal Syndrome; Treatment Outcome

2018